Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 10/2018

01-10-2018 | Nephrology - Original Paper

Ghrelin and acyl ghrelin levels are associated with inflammatory and nutritional markers and with cardiac and vascular dysfunction parameters in hemodialysis patients

Authors: Crina Claudia Rusu, Simona Racasan, Diana Moldovan, Alina Potra, Dacian Tirinescu, Cristian Budurea, Remus Orasan, Ioan Mihai Patiu, Cosmina Bondor, Dan Vladutiu, Dan Delean, Alexandra Danu, Ina Maria Kacso

Published in: International Urology and Nephrology | Issue 10/2018

Login to get access

Abstract

Purpose

Exogenous ghrelin is associated with cardiovascular protection in experimental and human studies. Nevertheless ESRD patients have increased ghrelin levels and severe cardiovascular comorbidities. This study aims to elucidate the metabolic factors influencing endogenous ghrelin/acyl ghrelin levels and to analyze the relation between endogenous ghrelin/acyl ghrelin levels and cardiac and vascular function markers in hemodialysis patients.

Methods

The cross-sectional study was conducted in hemodialysis patients (n = 88); 50 of them were men, mean age 61.1 ± 13.5 years, 17% had diabetes. We assessed nutritional and inflammatory status and analyzed the determinants of ghrelin/acyl ghrelin and their relation with cardiac and vascular function.

Results

Ghrelin is correlated with IL-1β (r = 0.88, p < 0.0001), triglycerides, total cholesterol (TC), and Kt/V. IL-1β is the strongest predictor of ghrelin levels (p < 0.0001). Acyl ghrelin is correlated with TC (r = 0.36, p = 0.001), LDL-cholesterol, serum bicarbonate, body mass index. TC is the strongest predictor for acyl ghrelin levels (p = 0.038). Patients with high ghrelin levels had significantly decreased nitroglycerin-mediated dilation (p = 0.05) and higher IL-1β levels (p < 0.001); increased NT-proBNP is associated with lower levels of acyl ghrelin (r = − 0.33, p = 0.02) in male patients.

Conclusion

The inflammatory marker IL-1β is in our study the strongest predictor of ghrelin levels while the nutritional marker-total cholesterol is the strongest predictor for acyl ghrelin levels in HD patients. High endogenous ghrelin level is associated with high IL-1β and with vascular smooth muscle cell dysfunction. Low acyl ghrelin level is associated with high NT-proBNP (a cardiac dysfunction marker) in male HD patients. There is a direct correlation between endogenous ghrelin level and inflammatory markers, which is not related with cardiovascular protection.
Literature
1.
Hosoda H, Kojima M, Matsuo H, Kangawa K (2000) Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279:909–913CrossRefPubMed
2.
Pérez-Fontán M, Cordido F, Rodríguez-Carmona A, Peteiro J, García-Naveiro R, García-Buela J (2004) Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 219:2095–2100CrossRef
3.
Xu L, Yu L, Chi N, Wang W, Liu G, Shi W (2016) Plasma ghrelin levels in association with left ventricular function and nutritional status in dialysis patients. Biomed Rep 5:45–49CrossRefPubMedPubMedCentral
4.
Akamizu T, Shinomiya T, Irako T, Fukunaga M, Nakai Y, Nakai Y, Kangawa K (2005) Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab 90:6–9CrossRefPubMed
5.
Muscaritoli M, Molfino A, Chiappini MG, Laviano A, Ammann T, Spinsanti P, Melchiorri D, Inui A, Alegiani F, Rossi Fanelli F (2007) Anorexia in hemodialysis patients: the possible role of des-acyl ghrelin. Am J Nephrol 27:360–365CrossRefPubMed
6.
Barros A, de F, Moraes, Pinto C, Lobo MB, Mafra JC D (2013) Is there association between acyl-ghrelin and inflammation in hemodialysis patients? J Bras Nefrol 35:120–126CrossRef
7.
Deng B, Fang F, Yang T, Yu Z, Zhang B, Xie X (2015) Ghrelin inhibits AngII-induced expression of TNF-α, IL-8, MCP-1 in human umbilical vein endothelial cells. Int J Clin Exp Med 8:579–588PubMedPubMedCentral
8.
Carrero JJ, Nakashima A, Qureshi AR, Lindholm B, Heimbürger O, Bárány P, Stenvinkel P (2011) Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int 79:749–756CrossRefPubMed
9.
Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huédé G, Saas P, Wendling D (2007) Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 56:1383–1389CrossRefPubMed
10.
Vila G, Maier C, Riedl M, Nowotny P, Ludvik B, Luger A, Clodi M (2007) Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J Clin Endocrinol Metab 92:3930–3934CrossRefPubMed
11.
Vanitha RN1, Kavimani S, Soundararajan P, Chamundeeswari D, Kannan G, Rengarajan S (2016) Ghrelin and its Association with Nutritional and Inflammatory Status of Patients on Maintenance Hemodialysis in a South Indian Tertiary Care Hospital Ann Med Health Sci Res 3:146–155CrossRef
12.
Pöykkö SM, Kellokoski E, Ukkola O, Kauma H, Päivänsalo M, Kesäniemi YA, Hörkkö S (2006) Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males. J Intern Med 260:43–52CrossRefPubMed
13.
Trimarchi H, Muryan A, Raña MS, Paggi P, Lombi F, Forrester M, Pomeranz V, Karl A, Alonso M, Young P, Dicugno M (2013) Proteinuria and its relation to diverse biomarkers and body mass index in chronic hemodialysis. Int J Nephrol Renovasc Dis 6:113–119CrossRefPubMedPubMedCentral
14.
15.
Enomoto M, Nagaya N, Uematsu M, Okumura H, Nakagawa E, Ono F, Hosoda H, Oya H, Kojima M, Kanmatsuse K, Kangawa K (2003) Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide. in healthy humans Clin Sci (Lond) 105:431–435CrossRef
16.
Rossi F, Bertone C, Petricca S, Santiemma V (2007) Ghrelin inhibits angiotensin II-induced migration of human aortic endothelial cells. Atherosclerosis 192:291–297CrossRefPubMed
17.
Hedayati N, Annambhotla S, Jiang J, Wang X, Chai H, Lin PH, Yao Q, Chen C (2009) Growth hormone-releasing peptide ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells. J Vasc Surg 49:199–207CrossRefPubMed
18.
Onofriescu M, Mardare NG, Segall L, Voroneanu L, Cuşai C, Hogaş S, Ardeleanu S, Nistor I, Prisadă OV, Sascău R, Covic A (2012) Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. Int Urol Nephrol 44:583–591CrossRefPubMed
19.
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115CrossRefPubMed
20.
Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351:2599–2610CrossRefPubMed
21.
Mafra D, Jolivot A, Chauveau P, Drai J, Azar R, Michel C, Fouque D (2010) Are ghrelin and leptin involved in food intake and body mass index in maintenance hemodialysis? J Ren Nutr 20:151–157CrossRefPubMed
22.
Huang CX, Yuan MJ, Huang H, Wu G, Liu Y, Yu SB, Li HT, Wang T (2009) Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides 30:2286–2291CrossRefPubMed
23.
Beberashvili I, Sinuani I, Azar A, Shapiro G, Feldman L, Doenyas-Barak K, Stav K, Efrati S (2017) Interaction between acyl-ghrelin and BMI predicts clinical outcomes in hemodialysis patients. BMC Nephrol 18:29CrossRefPubMedPubMedCentral
24.
Cohen RI1, Tsang D, Koenig S, Wilson D, McCloskey T, Chandra S (2008) Plasma ghrelin and leptin in adult cystic fibrosis patients J Cyst Fibros 5:398–402CrossRef
25.
Mafra D, Farage NE, Lobo JC, Stockler-Pinto MB, Leal VO, Carvalho DP, Leite M Jr (2011) Relationship between total ghrelin and inflammation in hemodialysis patients. Peptides 32:358–361CrossRefPubMed
26.
Madison LD, Scarlett JM, Levasseur P, Zhu X, Newcomb K, Batra A, Bowe D, Marks DL (2008) Prostacyclin signaling regulates circulating ghrelin during acute inflammation. J Endocrinol 196:263–273CrossRefPubMed
27.
Dixit VD, Yang H, Cooper-Jenkins A, Giri BB, Patel K, Taub DD (2009) Reduction of T cell-derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation. Blood 113:5202–5205CrossRefPubMedPubMedCentral
28.
Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C, Weintraub NL (2004) Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109:2221–2226CrossRefPubMed
29.
Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526CrossRefPubMed
30.
31.
Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Treviño-Becerra A, Wanner C (2008) A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73:391–398CrossRefPubMed
32.
Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbridge M, Brown EA, Taube DH, Ghatei MA, Tam FW, Bloom SR, Choi P (2009) Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 76:199–206CrossRefPubMed
33.
Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A (2009) Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 61:430–481CrossRefPubMed
34.
Rodriguez Ayala E, Pecoits-Filho R, Heimbürger O, Lindholm B, Nordfors L, Stenvinkel P (2004) Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant 19:421–426CrossRefPubMed
35.
Mafra D, Guebre-Egziabher F, Cleaud C, Arkouche W, Mialon A, Drai J, Fouque D (2010) Obestatin and ghrelin interplay in hemodialysis patients. Nutrition 26:1100–1104CrossRefPubMed
36.
Lee CJ, Subeq YM, Wang CH, Lee RP, Fang TC, Hsu BG (2008) Fasting serum ghrelin level is associated with metabolic syndrome in peritoneal dialysis patients. Perit Dial Int 28(Suppl 3):S196–S200PubMed
37.
Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members (2014) KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85:1303–1309CrossRefPubMed
38.
39.
Schwermer K, Hoppe K, Radziszewska D, Kłysz P, Sawatiuk P, Nealis J, Kałużna M, Kaczmarek J, Baum E, Lindholm B, Pawlaczyk K, Oko A (2015) Nterminal proB-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis. Pol Arch Med Wewn 125:560–569PubMed
40.
Satyan S, Light RP, Agarwal R (2007) Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 50:1009–1019CrossRefPubMedPubMedCentral
41.
Chen Y, Ji XW, Zhang AY, Lv JC, Zhang JG, Zhao CH (2014) Prognostic value of plasma ghrelin in predicting the outcome of patients with chronic heart failure. Arch Med Res 45:263–369CrossRefPubMed
42.
43.
Zhang GG, Cai HQ, Li YH, Sui YB, Zhang JS, Chang JR, Ning M, Wu Y, Tang CS, Qi YF, Yin XH (2013) Ghrelin protects heart against ERS-induced injury and apoptosis by activating AMP-activated protein kinase. Peptides 48:156–165CrossRefPubMed
44.
Fahim MA, Hayen A, Horvath AR, Dimeski G, Coburn A, Johnson DW, Hawley CM, Campbell SB, Craig JC (2015) N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol 10:620–629CrossRefPubMedPubMedCentral
45.
46.
Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ (2005) B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46:610–620CrossRefPubMed
47.
Caliskan Y, Gorgulu N, Yelken B, Yazici H, Oflaz H, Elitok A, Turkmen A, Bozfakioglu S, Sever MS (2009) Plasma ghrelin levels are associated with coronary microvascular and endothelial dysfunction in peritoneal dialysis patients. Ren Fail 31:807–813CrossRefPubMed
48.
Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Higashi Y (2013) Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol 33:1401–1408CrossRefPubMed
49.
Dalton BS, Fassett RG, Geraghty DP, De Ryke R, Coombes JS (2011) Vascular function and mortality in haemodialysis patients: a pilot study. Arch Cardiovasc Dis 104:518–523CrossRefPubMed
50.
Akamatsu D, Sato A, Goto H, Watanabe T, Hashimoto M, Shimizu T, Sugawara H, Sato H, Nakano Y, Miura T, Zukeran T, Serizawa F, Hamada Y, Tsuchida K, Tsuji I, Satomi S (2010) Nitroglycerin-mediated vasodilatation of the brachial artery may predict long-term cardiovascular events irrespective of the presence of atherosclerotic disease. J Atheroscler Thromb 17:1266–1274CrossRefPubMed
51.
Rusu CC, Ghervan L, Racasan S, Kacso I, Moldovan D, Potra A, Bondor C, Anton F, Patiu IM, Caprioara MG (2016) Nitroglycerin mediated dilation evaluated by ultrasound is associated with sTWEAK in hemodialysis patients. Med Ultrason 18:57–63CrossRefPubMed
52.
dell’Oglio MP, Simone S, Ciccone M, Corciulo R, Gesualdo M, Zito A, Cortese F, Castellano G, Gigante M, Gesualdo L, Grandaliano G, Pertosa GB (2017) Neutrophil-dependent pentraxin-3 and reactive oxygen species production modulate endothelial dysfunction in haemodialysis patients. Nephrol Dial Transplant 32:1540–1549PubMed
53.
Bouros D, Tzouvelekis A, Anevlavis S, Doris M, Tryfon S, Froudarakis M, Zournatzi V, Kukuvitis A (2006) Smoking acutely increases plasma ghrelin concentrations. Clin Chem 52:777–778CrossRefPubMed
54.
Koopmann A, Bez J, Lemenager T, Hermann D, Dinter C, Reinhard I, Hoffmann H, Wiedemann K, Winterer G, Kiefer F (2015) Effects of cigarette smoking on plasma concentration of the appetite-regulating peptide ghrelin. Ann Nutr Metab 66:155–161CrossRefPubMed
Metadata
Title
Ghrelin and acyl ghrelin levels are associated with inflammatory and nutritional markers and with cardiac and vascular dysfunction parameters in hemodialysis patients
Authors
Crina Claudia Rusu
Simona Racasan
Diana Moldovan
Alina Potra
Dacian Tirinescu
Cristian Budurea
Remus Orasan
Ioan Mihai Patiu
Cosmina Bondor
Dan Vladutiu
Dan Delean
Alexandra Danu
Ina Maria Kacso
Publication date
01-10-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 10/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1933-7

Other articles of this Issue 10/2018

International Urology and Nephrology 10/2018 Go to the issue

Urology - Original Paper

miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a

Urology - Original Paper

Small-angle X-ray scattering (SAXS) and nitrogen porosimetry (NP): two novel techniques for the evaluation of urinary stone hardness

Nephrology - Original Paper

An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a Bayesian network meta-analysis

Nephrology - Original Paper

The unexpected presence of iron in bone biopsies of hemodialysis patients

Urology - Review

Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies

Urology - Original Paper

Management of failed hypospadias: choosing the right method and achieving optimal results
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits